Fig. 2From: Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphomaLongitudinal evaluation of hepatitis B virus (HBV)–DNA, liver enzymes, and bilirubin. a The dynamic changes in ALT, AST and total bilirubin before and after CAR T cell therapy. b HBV-DNA copies before and after CAR T cell therapyBack to article page